Akebia Therapeutics Inc. (AKBA)


Stock Price Forecast

March 27, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Akebia Therapeutics Inc. chart...

About the Company

akebia therapeutics, inc. is a biopharmaceutical company headquartered in cambridge, massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor (hif) biology. akebia’s lead product candidate, vadadustat, is an investigational oral therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. akebia’s global phase 3 program for vadadustat, which includes the pro2tect studies for non-dialysis patients with anemia associated with chronic kidney disease and the inno2vate studies for dialysis-dependent patients, is currently ongoing. for more information, please visit our website at www.akebia.com.

CEO

John Butler

Exchange

NASDAQ

Website

https://akebia.com/

$194M

Total Revenue

353

Employees

$436M

Market Capitalization

-6.55

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $AKBA News

Akebia (AKBA) Up as Vafseo Gets FDA Nod for Anemia Due to CKD

14h ago, source: Zacks.com on MSN

Akebia Therapeutics, Inc. AKBA announced that the FDA has approved its Vafseo (vadadustat) tablets for the treatment of ...

After a struggle, Akebia’s oral CKD drug is approved by the FDA

3h ago, source: BioWorld

After a complete response letter (CRL) from the U.S. FDA in 2022 and approvals in Europe, Japan and Australia, Akebia ...

FDA Approves For Akebia Therapeutics' Vafseo For Kidney Disease Associated Anemia

on MSN ago, source:

Vafseo (vadadustat) tablets for anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at ...

Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis

1d ago, source:

Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people ...

Akebia's Vafseo finally gets its shot at US chronic kidney disease market after FDA approval

12h ago, source: FiercePharma

Akebia never lost confidence in its oral chronic kidney disease (CKD) anemia drug Vafseo, even after the FDA nixed its first ...

Akebia's Vafseo Tablets Approved By FDA For Anemia Treatment In Dialysis Patients

23h ago, source:

Akebia Therapeutics Inc. (AKBA) said that the U.S. Food and Drug Administration has approved Vafseo or vadadustat Tablets for the ...

Akebia stock jumps as FDA clears renal anemia therapy

on MSN ago, source:

Akebia Therapeutics (AKBA) receives FDA approval for Vafseo tablets, leading to a 25% surge in premarket shares.

Two years after initial rejection, Akebia’s anemia drug finally gets FDA approval

2d ago, source: The Business Journals

Two years after Akebia Therapeutics received a rejection letter from the U.S. Food and Drug Administration over a drug it ...

Akebia’s CKD Anemia Drug Ends Tough Regulatory Path with FDA Approval

12h ago, source: BioSpace

After an initial rejection due to safety issues, followed by a dispute and deferred actions, Akebia Therapeutics on Wednesday ...

Akebia’s Vafseo gains FDA approval for anaemia due to CKD

12h ago, source: Pharmaceutical Technology on MSN

The US FDA has granted approval for Akebia Therapeutics' Vafseo tablets for anaemia caused by chronic kidney disease (CKD).

Akebia joins GSK in US market for oral CKD anaemia drugs

11h ago, source: pharmaphorum

The FDA has approved Akebia Therapeutics’ vadadustat as a treatment for anaemia caused by chronic kidney disease (CKD) in ...

Akebia Awaits FDA Word On Second Crack At Vadadustat

2d ago, source:

An FDA decision looms for Akebia Therapeutics and its proposed vadadustat treatment for anemia due to chronic kidney disease in adults on dialysis. The FDA, which turned away Akebia's initial ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...